Picture loading failed.

Anti-INSR therapeutic antibody (Pre-made Valanafusp biosimilar,Whole mAb Fusion) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Valanafusp alpha is a BBB-penetrating form of IDUA, and is designed to deliver the IDUA enzyme to brain cells to reverse the accumulation of heparan sulfate (HS) GAGs and lysosomal inclusions. The primary therapeutic goal of valanafusp alpha therapy is stabilization of cognitive decline in severe MPSI.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-608-1mg 1mg 3090
GMP-Bios-ab-608-10mg 10mg 21890
GMP-Bios-ab-608-100mg 100mg 148000
GMP-Bios-ab-608-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-INSR therapeutic antibody (Pre-made Valanafusp biosimilar,Whole mAb Fusion)
INN Name Valanafusp
TargetINSR
FormatWhole mAb Fusion
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI Structure5kqv:PQ:CD/4zxb:CD
95-98% SI Structure3loh:CD/2dtg:CD/3w14:CD:PQ
Year Proposed2017
Year Recommended2018
CompaniesArmaGen Technologies
Conditions Approvedna
Conditions ActiveMucopolysaccharidosis I
Conditions Discontinuedna
Development Techna